Clinical-Stage RNAi Developer City Therapeutics Files for Nasdaq IPO
核心洞察
City Therapeutics (搜索) filed an S-1 on September 24, 2026 to list on the Nasdaq Global Market under the ticker CTY, with Goldman Sachs, Jefferies, Stifel and Oppenheimer as lead underwriters.
Proceeds are earmarked for CITY-FXI (搜索) through Phase 1 and a planned Phase 2 total knee arthroplasty study, plus CITY-RBP4 (搜索) and CITY-TFR2 (搜索) development.
CITY-FXI (搜索) is a GalNAc-conjugated siRNA targeting Factor XI (搜索) that showed dose-dependent FXI knockdown in healthy volunteers, aiming to cut bleeding risk versus current anticoagulants.
City Therapeutics (搜索), a clinical-stage developer of RNA interference medicines, filed an S-1 on September 24, 2026 to go public on the Nasdaq Global Market under the ticker CTY. Goldman Sachs, Jefferies, Stifel and Oppenheimer are lead underwriters. Proceeds will fund clinical trials for the company's lead programs in thrombosis (搜索), Stargardt disease (搜索) and anemia of chronic disease (搜索), along with further platform development.
The lead asset, CITY-FXI (搜索), is a GalNAc-conjugated siRNA targeting Factor XI (搜索) intended to prevent pathological thrombosis (搜索) while reducing bleeding risk relative to current anticoagulants. Phase 1 data in healthy volunteers showed dose-dependent FXI knockdown, and a Phase 2 study in total knee arthroplasty is planned. CITY-RBP4 (搜索) targets retinol binding protein 4 (搜索) to reduce toxic vitamin A byproducts in Stargardt disease (搜索), with a Phase 1 start planned for late 2026 and potential expansion into geographic atrophy (搜索). CITY-TFR2 (搜索) targets transferrin receptor 2 (搜索) to lower hepcidin and restore iron availability in anemia of chronic disease (搜索), beginning with an investigator-initiated trial in myelofibrosis (搜索)-associated anemia in China in late 2026 and a company-sponsored Phase 1/2 in early 2027.
The City Platform combines RNAi trigger engineering, including proprietary cityRNA triggers, tissue-targeted delivery ligands such as LRP1 for ocular and CNS indications, and AI/ML-enabled design. Collaborations with Bausch + Lomb (搜索) in retinal diseases and Biogen in CNS neurodegenerative diseases sit alongside the wholly owned pipeline. City Therapeutics (搜索) reported $13.6 million in collaboration revenue for 2025, up from $2.8 million in 2024, a loss from operations of $59.9 million and a net loss of $58.5 million, with 81 full-time employees as of September 1, 2026.
Source: TradingView